2023-06-07 07:23:14 ET
- Satellos Bioscience ( OTC:MSCLF ) on Wednesday notifies the appointment of Alan K. Jacobs, MD as Chief Medical Officer of the company, effective June 7, 2023.
- Dr. Jacobs, most recently served as Vice President, Clinical Development, Neuroscience for Boston Pharmaceuticals.
- In connection with his appointment , the company has granted Dr. Jacobs a total of 1.1M stock options, exercisable at a price of $0.56/share for a period of 10 years from the date of grant and vest over a period of four years.
For further details see:
Satellos Bioscience appoints Alan K. Jacobs as Chief Medical Officer